Tyagi Neha, Gawhale Siddhi, Patil Manojkumar G, Tambolkar Sampada, Salunkhe Shradha, Mane Shailaja V
Pediatrics, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth (Deemed to be University) Pimpri, Pune, IND.
Cureus. 2024 Jul 26;16(7):e65427. doi: 10.7759/cureus.65427. eCollection 2024 Jul.
Background Sepsis poses a critical medical challenge due to its profound systemic inflammatory response, which frequently results in organ dysfunction and high mortality rates, especially in pediatric patients. The condition requires prompt recognition and aggressive management to mitigate its severe outcomes. Methods This prospective study enrolled 248 pediatric patients admitted with sepsis to the pediatric intensive care unit (PICU) at our tertiary care center. Patients were randomly assigned to either the C-reactive protein (CRP) or procalcitonin (PCT) groups, with biomarker levels measured upon admission (hour zero) and again at 72 hours post-admission. Clinical parameters such as the need for ionotropic support, use of steroids, incidence of acute kidney injury (AKI), requirement for invasive ventilation, patient outcomes, and changes in antibiotic management were assessed based on these biomarker levels. Results Procalcitonin-positive sepsis cases demonstrated notable clinical severity compared to their C-reactive protein counterparts, showing significantly lower systolic blood pressure (p = 0.012), heightened need for ionotropic support (p < 0.0001), and more pronounced liver and renal dysfunction as indicated by elevated serum bilirubin (p = 0.001) and creatinine levels (p = 0.0058). The incidence of AKI was also higher in procalcitonin-positive cases. Despite these severe clinical parameters, there were no significant differences in the length of the PICU stay or in patient outcomes concerning discharge and mortality rates. Procalcitonin levels effectively guided antibiotic management, resulting in therapy adjustments in a substantial proportion of cases, with 67 (54%) experiencing downgrades and 33 (27%) requiring upgrades based on procalcitonin levels measured 72 hours post-admission. Conclusion Procalcitonin proves to be a valuable biomarker in assessing the severity and management of sepsis in pediatric patients. It correlates significantly with clinical parameters such as blood pressure, the need for ionotropic support, and markers of organ dysfunction.
脓毒症因其严重的全身炎症反应而构成严峻的医学挑战,这种反应常常导致器官功能障碍和高死亡率,尤其是在儿科患者中。该病症需要迅速识别和积极治疗以减轻其严重后果。方法:这项前瞻性研究纳入了248名因脓毒症入住我们三级医疗中心儿科重症监护病房(PICU)的儿科患者。患者被随机分配到C反应蛋白(CRP)组或降钙素原(PCT)组,入院时(零小时)及入院后72小时再次测量生物标志物水平。基于这些生物标志物水平评估临床参数,如是否需要使用血管活性药物支持、是否使用类固醇、急性肾损伤(AKI)的发生率、有创通气的需求、患者预后以及抗生素管理的变化。结果:与C反应蛋白组相比,降钙素原阳性的脓毒症病例显示出明显的临床严重程度,收缩压显著更低(p = 0.012),对血管活性药物支持的需求更高(p < 0.0001),血清胆红素升高(p = 0.001)和肌酐水平升高(p = 0.0058)表明肝肾功能障碍更明显。降钙素原阳性病例中AKI的发生率也更高。尽管有这些严重的临床参数,但在PICU住院时间以及出院和死亡率方面的患者预后并无显著差异。降钙素原水平有效地指导了抗生素管理,在很大一部分病例中导致了治疗调整,根据入院后72小时测量的降钙素原水平,67例(54%)治疗降级,33例(27%)需要升级。结论:降钙素原被证明是评估儿科患者脓毒症严重程度和管理的有价值的生物标志物。它与血压、血管活性药物支持需求和器官功能障碍标志物等临床参数显著相关。